News stories about GlaxoSmithKline (NYSE:GSK) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlaxoSmithKline earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the pharmaceutical company an impact score of 45.5034714808708 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- GlaxoSmithKline (GSK) Downgraded to “Neutral” at Bank of America (americanbankingnews.com)
- Glistening Stock’s Review: GlaxoSmithKline plc (NYSE: GSK) (alphabetastock.com)
- GlaxoSmithKline (GSK) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
- GlaxoSmithKline (GSK) Upgraded at BNP Paribas (americanbankingnews.com)
- Analytical Guide for two rising stock’s: McDermott International, Inc., (NYSE: MDR), GlaxoSmithKline plc, (NYSE: GSK) (globalexportlines.com)
NYSE GSK opened at $39.79 on Thursday. The stock has a market cap of $97,392.16, a price-to-earnings ratio of 13.82, a P/E/G ratio of 2.19 and a beta of 0.84. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be given a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a dividend yield of 6.36%. The ex-dividend date is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 87.85%.
Several brokerages recently issued reports on GSK. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday. BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday. JPMorgan Chase restated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, January 29th. Deutsche Bank restated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, March 28th. Finally, ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.37.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.